Company Insights

CERT customer relationships

Explore interactive graphBrowse insights index
CERT customer relationship map

Certara (CERT): Regulatory wins compound a subscription-and-license business with services attached

Certara (NASDAQ: CERT) sells biosimulation software and complementary scientific services to biopharma and regulators, monetizing through a mix of software licenses, cloud subscriptions, annual maintenance, and technology-enabled consulting that supports regulatory submissions. The company captures value where its tools replace or de-risk clinical work, driving both one-time license revenue and recurring annuity-like subscription/maintenance fees. For investors, the model is software-plus-services with high regulatory stickiness and concentrated counterparty importance.
Discover more on the platform that tracks these customer relationships: https://nullexposure.com/

A concrete regulatory validation that moves the revenue needle

Certara’s Simcyp Simulator being accepted by the FDA as a substitute for clinical studies is not a theoretical capability — it is now operationally material for customers that pursue Model-Informed Drug Development (MIDD). That acceptance translates into direct commercial leverage for Certara’s software and consultative services because it reduces clients’ time and cost to approval, which supports willingness to pay for licensed tools and project execution.

Novartis Biomedical Research — FDA acceptance for asciminib (Scemblix)

Novartis used Certara’s Simcyp Simulator to produce PBPK modeling accepted by the U.S. FDA in lieu of clinical studies supporting the NDA for asciminib (Scemblix), illustrating a clear regulatory acceptance pathway for Simcyp-based modeling. Source: Certara announcement carried by Bitget, March 9, 2026 (https://www.bitget.com/amp/news/detail/12560605234251).

Novartis — reinforcement in secondary reporting

A separate report reiterated Novartis’s endorsement of Simcyp’s scientific rigor and its role within the Simcyp Consortium, reinforcing that large pharmas are integrating Certara’s tools into regulatory strategies. Source: StockTitan, March 9, 2026 (https://www.stocktitan.net/news/CERT/certara-simcyp-simulator-results-replace-ten-human-trials-for-kut0m3yl8t04.html).

How Certara’s customer contracts actually work — the commercial mechanics

Certara’s public disclosures make its contracting posture explicit and investor-relevant: the company combines upfront software license fees, ratable subscription revenues (typically one to three years), and annual maintenance recognized over one-year terms. The business also sells technology-enabled services delivered by domain scientists to apply biosimulation on client projects. These features define revenue cadence and renewal risk:

  • Licensing and upfront fees create episodic revenue spikes tied to major client deployments. Evidence: company language on recognizing license fees upon delivery.
  • Subscriptions and maintenance supply recurring revenue, recognized ratably, improving predictability when retention holds. Evidence: subscription and maintenance terms typically one to three years or annually.
  • Services revenue supplements software sales and often accompanies regulatory filings, increasing deal economics but adding delivery risk and margin variability.

These contracting characteristics create a mixed revenue profile: recurring backbone plus transaction-driven upsides.

Explore recurring relationship signals and deeper customer intelligence at https://nullexposure.com/

Company-level relationship signals that change the investment thesis

Several constraints from Certara’s filings and disclosures offer company-wide insights that should shape valuation and due diligence—these are not tied to any single customer unless explicitly stated:

  • Contract type mix: Licensing, subscription, and short-term maintenance are core; subscription terms commonly run one to three years while maintenance is typically annual. This structure supports recurring revenue but concentrates renewal risk into short windows.
  • Counterparty breadth and criticality: Certara reports customers across industry and government, including the FDA and other regulatory agencies; its products are used by more than 94,000 users and by 23 global drug regulatory agencies, indicating high penetration in the regulatory workflow and elevated product criticality.
  • Global footprint: The company operates globally and sells to multinational biopharma and government entities, giving product-market diversification but also exposure to regulatory timing across jurisdictions.
  • Role breadth: Certara operates both as licensor (selling software) and service provider (delivering consulting and regulatory support), which increases total addressable spend per client but also mixes software gross margins with lower-margin human capital.
  • Relationship stage: The company signals an active installed base with measured net retention metrics, implying an emphasis on upsell and renewals rather than purely transactional sales.

Collectively, these signals make Certara a platform provider embedded in drug development workflows, with revenue resilience tied to retention and expansion among regulated sponsors and agencies.

What investors should price in: concentration, renewals, and regulatory dependence

Certara’s commercial strengths are identical to its core risks. The high criticality of software for regulatory submissions supports pricing power with large sponsors, but the short contract rhythm for maintenance and subscriptions concentrates renewal events and amplifies churn risk if clients change strategies. Government and regulator relationships add credibility and potential long sales cycles; they also introduce single-counterparty sensitivities when a small number of large biopharma customers drive a material share of revenues.

  • Upside drivers: Continued regulatory acceptance of PBPK and MIDD use cases will increase demand for Simcyp and related services, supporting expansion revenue and license conversions.
  • Downside drivers: Failed renewals, pricing pressure from competitors, or slower adoption of MIDD by late-stage sponsors would compress revenue and margins given the mixed software-and-services model.

Tactical takeaways and next steps for investors

  • Certara’s revenue model is hybrid: recurring subscription/maintenance plus sizable one-time license and services revenue. That combination creates a growth multiple that hinges on retention and the pace of regulatory acceptance.
  • Regulatory wins—like Novartis’s use of Simcyp for asciminib—are material commercial catalysts because they reduce client development costs and increase the value proposition for licensing Simcyp.
  • Monitor net retention and renewal terms closely as the most direct leading indicators of durable ARR and margin expansion.

For deeper tracking of Certara’s evolving customer map and to receive alerts when new regulatory validations are reported, visit https://nullexposure.com/

Final recommendation

Certara is a specialized software-and-services platform whose valuation should reflect both its embedded regulatory utility and the concentrated renewal cadence inherent in one- to three-year contracts. Investors seeking exposure to regulatory-driven software adoption should weigh Certara’s demonstrated ability to substitute clinical work against renewal and delivery risks tied to short-term maintenance cycles. For ongoing coverage of customer relationships, regulatory acceptances, and contract signals relevant to Certara, see https://nullexposure.com/ — the hub for investor-grade customer intelligence.